How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,912 results for

physical therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Planning, initiation & withdrawal of Renal Replacement Therapy

Planning, initiation & withdrawal of Renal Replacement Therapy - 1 - CLINICAL PRACTICE GUIDELINE Planning, Initiating and Withdrawal of Renal Replacement Therapy UK Renal Association 6 th Edition Final Version (based on literature up to Feb 2013) Graham Warwick, Consultant Nephrologist Andrew Mooney, Consultant Nephrologist Lynne Russon, Consultant in Palliative Medicine, Rebecca Hardy, SpR in Nephrology Posted at www.renal.org/guidelines Please check for updates Please send feedback (...) for the next edition to Graham Warwick at graham.warwick@uhl-tr.nhs.uk or Andrew Mooney at andrew.mooney@leedsth.nhs.uk - 2 - Contents Introduction Summary of Clinical Practice Guidelines for Planning, Initiating and Withdrawal of Renal Replacement Therapy 1. Timely nephrology referral (Guidelines 1.1-1.2) 2. Nephrology follow-up (Guidelines 2.1-2.3) 3. Preparing for renal replacement therapy (Guidelines 3.1-3.7) 4. Educating patients and carers for renal replacement therapy (Guidelines 4.1-4.3) 5

2014 Renal Association

22. Treatment of HIV-1-positive adults with antiretroviral therapy (interim update)

Treatment of HIV-1-positive adults with antiretroviral therapy (interim update) © 2016 British HIV Association _________________________________________________________________________________________________________________________ British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update) NHS Evidence has accredited the process used by the British HIV Association (BHIVA) to produce guidelines. Accreditation is valid (...) for five years from July 2012 and is applicable to guidance produced using the processes described in the British HIV Association (BHIVA) Guideline Development Manual. More information on accreditation can be viewed at www.nice.org.uk/accreditation August 2016 1 BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update) Writing Group Laura Waters Chair N Ahmed, B Angus, M Boffito, M Bower, D Churchill, D Dunn, S Edwards, C Emerson, S Fidler, †M

2017 British HIV Association

23. Chemo- and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer

Chemo- and Targeted Therapy for Women with HER2 Negative (or unknown) Advanced Breast Cancer Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2014.56.7479 (...) Journal of Clinical Oncology - published online before print September 2, 2014 PMID: Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline x Ann H. Partridge , x R. Bryan Rumble , x Lisa A. Carey , x Steven E. Come , x Nancy E. Davidson , x Angelo Di Leo , x Julie Gralow , x Gabriel N. Hortobagyi , x Beverly Moy , x Douglas Yee , x Shelley B. Brundage , x

2014 American Society of Clinical Oncology Guidelines

24. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

alternative antineoplastic therapy over resuming ICPis if the skin irAE does not resolve to grade 1 or less. If ICPis are the patient’s only option, consider restarting once these adverse effects have resolved to a grade 1 level. 1.2 Bullous Dermatoses Recommendation 1.2a – Diagnostic Work-up. It is recommended that for all grades of irAEs the diagnostic work-up should include the following: Comprehensive physical examination, including evaluation of all mucous membranes. Rule out any other etiology (...) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2017.77.6385 Journal of Clinical

2018 American Society of Clinical Oncology Guidelines

25. The Joint IAEA, EANM, and SNMMI Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors

The Joint IAEA, EANM, and SNMMI Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors GUIDELINES The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours John J. Zaknun & L. Bodei & J. Mueller-Brand & M. E. Pavel & R. P. Baum & D. Hörsch & M. S. O’Dorisio & T. M. O’Dorisiol & J. R. Howe & M. Cremonesi & D. J. Kwekkeboom Published online: 7 February 2013 # The Author(s) 2013. This article (...) is published with open access at Springerlink.com Abstract Peptidereceptorradionuclidetherapy(PRRNT)isa molecularly targeted radiation therapy involving the systemic administrationofaradiolabelledpeptidedesignedtotargetwith high affinity and specificity receptors overexpressed on tumours. PRRNTemploying the radiotagged somatostatin re- ceptoragonists 90 Y-DOTATOC([ 90 Y-DOTA 0 ,Tyr 3 ]-octreotide) or 177 Lu-DOTATATE ([ 177 Lu-DOTA 0 ,Tyr 3 ,Thr 8 ]-octreotideor [ 177 Lu-DOTA 0 ,Tyr 3 ]-octreotate) have

2013 Society of Nuclear Medicine and Molecular Imaging

26. Role of Adjuvant Therapy in the Management of Early Stage Cervical Cancer

Role of Adjuvant Therapy in the Management of Early Stage Cervical Cancer Date of origin: 2011 Last review date: 2014 ACR Appropriateness Criteria ® 1 Early Stage Cervical Cancer American College of Radiology ACR Appropriateness Criteria ® ROLE OF ADJUVANT THERAPY IN THE MANAGEMENT OF EARLY-STAGE CERVICAL CANCER Expert Panel on Radiation Oncology–Gynecology: Aaron H. Wolfson, MD 1 ; Mahesh A. Varia, MD 2 ; David Moore, MD 3 ; Guatam G. Rao, MD 4 ; Higinia Rosa Cardenes, MD, PhD 5 ; Mohamed (...) a single institution’s prospective database [9]. Another single institutional retrospective study showed that in patients having RAH with FIGO stages IA2 to IIB, radical parametrectomy or radical trachelectomy in conjunction with PL achieved excellent survival with only 22% of the patients requiring postoperative radiation therapy (PORT) [10]. However, the total number of pelvic nodes to be harvested at the time of RAH has not been clearly established [11]. Moreover, the use of sentinel lymph node

2014 American College of Radiology

27. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: Injection therapies, low-back pain, and lumbar fusion

Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: Injection therapies, low-back pain, and lumbar fusion J Neurosurg Spine 21:79–90, 2014 79 ©AANS, 2014 J Neurosurg: Spine / Volume 21 / July 2014 Therapeutic Recommendations There is no new evidence that conflicts with the pre - vious recommendations regarding injection therapies pub- lished in the original version of the “Guidelines for the per - formance of fusion procedures (...) Injections Grade B Intraarticular injections of lumbar facet joints are not suggested for the treatment of facet-mediated chronic low-back pain without radiculopathy in cases of degen- erative disease of the lumbar spine (single Level II study and single Level III study). Lumbar medial nerve blocks are suggested for the Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: Injection therapies, low-back pain, and lumbar fusion William C. W atters

2014 Congress of Neurological Surgeons

28. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 14: Brace therapy as an adjunct to or substitute for lumbar fusion

Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 14: Brace therapy as an adjunct to or substitute for lumbar fusion J Neurosurg Spine 21:91–101, 2014 91 ©AANS, 2014 J Neurosurg: Spine / Volume 21 / July 2014 Recommendations There is no evidence that conflicts with the previous recommendations published in the original version of the guidelines for the use of lumbar bracing in the treatment of low-back pain. Grade B The prescription (...) , & tantalum markers were placed at that time. Pts were followed w/ RSA at various time points up to 1 yr. In Group I, 8 of 11 pts had a higher fusion rate based on no translation on RSA compared w/ 2 of 11 pts in Group II. Movement was assessed by sagittal, vertical, & transverse translation. The motion subsided btwn the 3- & 6-mo exams. Axelsson et a l . , 1 9 9 5 III All pts who were to undergo fusion for LBP had a trial of rigid or semi-rigid brace therapy for at l e a s t 3 w ks . P a i n i m p r o v

2014 Congress of Neurological Surgeons

29. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults 449 journal.publications.chestnet.org Pha r maco logic Th erapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report Darren B. Taichman , MD, PhD, FCCP ; Joe Ornelas , MS ; Lorinda Chung , MD ; James R. Klinger , MD, FCCP ; Sandra Lewis , PhD ; Jess Mandel , MD ; Harold I. Palevsky , MD, FCCP ; Stuart Rich , MD, FCCP ; Namita Sood , MD, FCCP ; Erika B. Rosenzweig , MD ; Terence K. Trow , MD (...) , FCCP ; Rex Yung , MD, FCCP ; C. Gregory Elliott , MD, FCCP ; and David B. Badesch , MD, FCCP OBJECTIVE: Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. Th e objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence. METHODS: Th is guideline was based on systematic reviews of English language evidence pub- lished between 1990

2014 American College of Chest Physicians

30. Cervical Arterial Dissections and Association With Cervical Manipulative Therapy

by members of the allopathic, osteopathic, and physical therapy/physiotherapy professions. According to the 2007 US statistics on alternative medicine, at least 38% of US adults and 12% of children use some form of alternative medicine, including chiropractic and osteopathic manipulations, mainly for back, neck, and joint pain. The chiropractic profession is common in the United States, Canada, and Australia but less so elsewhere. Chiropractic is the largest alternative medical profession in the United (...) Cervical Arterial Dissections and Association With Cervical Manipulative Therapy Cervical Arterial Dissections and Association With Cervical Manipulative Therapy | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Cervical Arterial

Full Text available with Trip Pro

2014 American Heart Association

31. Compounded Bioidentical Menopausal Hormone Therapy

Compounded Bioidentical Menopausal Hormone Therapy Compounded Bioidentical Menopausal Hormone Therapy - ACOG Menu ▼ Compounded Bioidentical Menopausal Hormone Therapy Page Navigation ▼ Number 532, August 2012 (Replaces No. 387, November 2007 and No. 322, November 2005) (Reaffirmed 2018) Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee This document reflects emerging clinical and scientific advances as of the date issued and is subject (...) to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Compounded Bioidentical Menopausal Hormone Therapy ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall effectiveness, has reinforced its usefulness for short-term treatment of menopausal symptoms. Menopausal therapy has been provided

2012 American College of Obstetricians and Gynecologists

32. Integrative Therapies During and After Breast Cancer Treatment

Integrative Therapies During and After Breast Cancer Treatment Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2018.79.2721 Journal of Clinical Oncology - published online before print June 11, 2018 PMID: Integrative Therapies During (...) Wellness for Life, Shawnee, KS; Sarah Cannon Cancer Institute, Kansas City, MO; Dawn M. Mussallem, The Mayo Clinic, Jacksonville, FL; Erin Price, Smith Center for Healing and the Arts, Washington, DC; Susan Rafte, Houston, TX; and Lorenzo Cohen, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract Section: Purpose The Society for Integrative Oncology (SIO) produced an evidence-based guideline on use of integrative therapies during and after breast cancer treatment

2018 American Society of Clinical Oncology Guidelines

33. Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

activity, adherence, AE profiles, and mechanism of action of DMTs when switching DMTs in people with MS with breakthrough disease activity during DMT use. Switching: Recommendation 3 Rationale Multiple DMTs are available for MS treatment. Switching therapies may be appropriate in people with MS who are experiencing AEs or complications with a DMT. Adherence to injectable DMTs is often incomplete. e23 Injection fatigue (physical or emotional) or injection-related pain or discomfort may be a common (...) Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis AAN Summary of Practice Guideline for Clinicians Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis AAN.com ©2018 American Academy of Neurology This is a summary of the American Academy of Neurology (AAN) publication, “Practice guideline recommendations: Disease-modifying therapies for adults with multiple sclerosis,” which was published in Neurology ®

2018 American Academy of Neurology

34. Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis 1 Practice guideline: Disease-modifying therapies for adults with multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Alexander Rae-Grant, MD 1 ; Gregory S. Day, MD, MSc 2 ; Ruth Ann Marrie, MD, PhD 3 ; Alejandro Rabinstein, MD 4 ; Bruce A.C. Cree, MD, PhD, MAS 5 ; Gary S. Gronseth, MD 6 ; Michael Haboubi (...) Academy of Neurology AEs: adverse effects ALT: alanine aminotransferase ARRs: annualized relapse rates AST: aspartate aminotransferase CIS: clinically isolated syndrome CMSC: Consortium of Multiple Sclerosis Centers” COI: conflict of interest CV: curriculum vitae DMTs: disease-modifying therapies EDSS: Expanded Disability Status Scale FDA: US Food and Drug Administration GDDI: Guideline Development, Dissemination, and Implementation Subcommittee IOM: Institute of Medicine mIUs: milli-international

2018 American Academy of Neurology

35. Water Treatment Facilities, Dialysis Water and Dialysis Fluid Quality for Haemodialysis and Related Therapies

Water Treatment Facilities, Dialysis Water and Dialysis Fluid Quality for Haemodialysis and Related Therapies 1 Guideline on water treatment systems, dialysis water and dialysis fluid quality for haemodialysis and related therapies Clinical Practice Guideline Prepared on behalf of The Renal Association 1 and The Association of Renal Technologists 2 January 2016 Review Date January 2020 All feedback to nahoenich@gmail.com NicholasHoenich 1,2 , Clinical Scientist, Newcastle University nahoenich (...) Clive Thompson– Employee of Alcontrol Laboratories, who perform a wide range of microbiological and chemical analysis for all water types. 3 Contents Introduction Summary of clinical practice guideline on water treatment systems, dialysis water and dialysis fluid quality for haemodialysis and related therapies 1. Clinical governance of water treatment systems for haemodialysis (Guidelines 1.1-1.3) 2. Planning and commissioning of water treatment systems for haemodialysis (Guidelines 2.1-2.3) 3

2016 Renal Association

36. Biologic therapy for psoriasis

, as defined by: · a 50% or greater reduction in baseline disease severity (for example, PASI 50 response, or % BSA where the PASI is not applicable) and · clinically relevant improvement in physical, psychological or social functioning (for example, a 4-point or greater improvement in DLQI or resolution of low mood) á R12 Consider changing to an alternative therapy, including another biologic therapy, if any of the following applies: · the psoriasis does not achieve the minimum response criteria (primary (...) of severe or unstable psoriasis if the biologic therapy were stopped · physical, psychological and social functioning if the biologic therapy were stopped · options for alternative, non-biologic treatment strategies áá R31 Assess whether biologic therapy for psoriasis can be stopped in women who become pregnant. Ensure consultation and information-sharing across specialities including with an obstetrician who has expertise in caring for pregnant women with medical problems. Collect pregnancy outcome

2017 British Association of Dermatologists

37. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen ultraviolet A (PUVA) therapy

British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen ultraviolet A (PUVA) therapy GUIDELINES BJD British Journal of Dermatology British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015 T.C. Ling, 1 T.H. Clayton, 1 J. Crawley, 2 L.S. Exton, 3 V. Goulden, 4 S. Ibbotson, 5 K. McKenna, 6 M.F. Mohd Mustapa, 3 L.E. Rhodes, 7 R (...) , and research support from Ambicare Health. T.C.L., T.H.C., J.C., V.G., S.I., K.McK, L.E.R., R.S. and R.S.D. are members of the guideline development group with technical support from L.S.E. and M.F.M.M. This is an updated set of guidelines prepared for the British Association of Dermatolo- gists (BAD) Clinical Standards Unit, which includes the Therapy & Guidelines (T&G) Subcommittee. Members of the Clinical Standards Unit that have been involved are P.M. McHenry (Chairman T&G), J.R. Hughes, M. Grif?ths

2016 British Association of Dermatologists

38. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications

Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 Free Access article Share (...) on Jump to Free Access article Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association , MD, FAHA , MD , MD , MD, MHS , MD, MSc , PharmD, MPH , MD, PhD , DDS , MD, FAHA , MD , MD, FAHA , MD , MD , PhD, RN and MD, FAHA PhD, FAHA Larry M. Baddour , Walter R. Wilson , Arnold S. Bayer , Vance G. FowlerJr , Imad M. Tleyjeh , Michael J. Rybak , Bruno Barsic , Peter B. Lockhart

Full Text available with Trip Pro

2016 Infectious Diseases Society of America

39. Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer

, Alberti G, Bisagni G, Botti E, Peracchia G. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat. 1984;4(4):309-313. 6. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830-849. 7. Bosch AM, Kessels AG, Beets GL, et al. Preoperative estimation of the pathological breast tumour size by physical examination (...) Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer New 2017 ACR Appropriateness Criteria ® 1 Monitoring Response to Neoadjuvant Chemotherapy American College of Radiology ACR Appropriateness Criteria ® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer Variant 1: Initial determination of tumor size and extent within the breast prior to neoadjuvant chemotherapy. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 9

2017 American College of Radiology

40. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

in the ICU that affect the timing and accuracy of IC measurements include the presence of air leaks or chest tubes, supplemental oxygen (e.g., nasal cannula, bilevel positive airway pressure), ventilator settings (fractional inspiratory oxygen and positive end-expiratory pressure), continuous renal replacement therapy (CRRT), anesthesia, physical therapy, and excessive movement ( ). More than 200 predictive equations have been published in the literature, with accuracy rates ranging from 40–75% when (...) Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient Guidelines for the Provision and Assessment of Nutrition Sup... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account

Full Text available with Trip Pro

2016 Society of Critical Care Medicine

Guidelines

Guidelines – filter by country